Singapore Institute of Advanced Medicine Holdings (Catalist:9G2) Full Year 2024 Results
Key Financial Results
-
Revenue: S$17.2m (up 5.9% from FY 2023).
-
Net loss: S$37.4m (loss widened by 97% from FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Singapore Institute of Advanced Medicine Holdings shares are down 15% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Singapore Institute of Advanced Medicine Holdings you should be aware of, and 2 of them are a bit unpleasant.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.